---
title: "Ascentage Pharma Outlines 2026 Global Innovation Strategy with Focus on Expanding Clinical Development, Advancing Product Commercialization, and Accelerating Pipeline Innovation in Hematologic Malignancies and Solid Tumors"
description: "Ascentage Pharma Group International has unveiled its 2026 global innovation strategy, focusing on expanding clinical development and product commercialization in hematologic malignancies and solid tu"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/272624215.md"
published_at: "2026-01-15T01:25:22.000Z"
---

# Ascentage Pharma Outlines 2026 Global Innovation Strategy with Focus on Expanding Clinical Development, Advancing Product Commercialization, and Accelerating Pipeline Innovation in Hematologic Malignancies and Solid Tumors

> Ascentage Pharma Group International has unveiled its 2026 global innovation strategy, focusing on expanding clinical development and product commercialization in hematologic malignancies and solid tumors. The plan includes advancing its innovative therapy pipeline, progressing multiple global Phase III trials, and developing APG-3288, a next-generation BTK degrader. The company aims to meet unmet clinical needs and enhance its global portfolio of products and clinical programs.

Ascentage Pharma Group International has announced its global innovation strategy for 2026, focusing on expanding its presence in hematologic malignancies and solid tumors. The company plans to accelerate global clinical development and product commercialization, with particular emphasis on advancing its pipeline of innovative therapies. Key future activities include progressing multiple global registrational Phase III trials and expanding the use of its proprietary protein degradation technology. The strategy also involves the clinical development of APG-3288, a next-generation BTK degrader, following investigational new drug clearance from the U.S. FDA. Ascentage Pharma aims to address unmet clinical needs worldwide and strengthen its global portfolio of commercialized products and late-stage clinical programs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9626156) on January 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [AAPG.US - Ascentage Pharma](https://longbridge.com/en/quote/AAPG.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nonprofit models support strategic boldness to develop gene therapies for rare diseases | Généthon CEO Frédéric Revah emphasizes the importance of nonprofit funding models in developing gene therapies for rare  | [Link](https://longbridge.com/en/news/277062424.md) |
| Balancing Emerging Clinical Momentum and Commercial Uncertainty: Maintaining a Hold on Arvinas Ahead of Key 2026 Readouts | TD Cowen analyst Tyler Van Buren has maintained a Hold rating on ARVN stock, citing a balance of emerging clinical momen | [Link](https://longbridge.com/en/news/276779831.md) |
| ZAWYA-PRESSR: P4ML becomes founding member of OTXL to support broader global access to ultra-rare disease treatments | P4ML, a UAE-based Future100 company, has become a Founding Member of the Orphan Therapeutics Accelerator (OTXL), enhanci | [Link](https://longbridge.com/en/news/276726002.md) |
| BUZZ-Larimar jumps on FDA's 'breakthrough' tag for neurological disorder therapy | Shares of therapy developer Larimar Therapeuticsjump 32% to $3.71 premarketCo says the U.S. FDA granted a breakthrough d | [Link](https://longbridge.com/en/news/276742755.md) |
| Larimar Therapeutics (LRMR) Surges On FDA Breakthrough Therapy Designation | Larimar Therapeutics (LRMR) shares surged 31.67% to $3.70 after the FDA granted Breakthrough Therapy Designation for its | [Link](https://longbridge.com/en/news/276770083.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.